Shots:
- The CHMP has granted a positive opinion to ADAMTS13 (rADAMTS13) for treating ADAMTS13 deficiency in cTTP children and adults
- The positive opinion was based on the P-III study assessing the efficacy, PK, safety, and tolerability for the same. Data was published in The New England Journal of Medicine in May 2024
- rADAMTS13 is a recombinant ADAMTS13 enzyme replacement therapy intended to treat cTTP. It is also being evaluating for iTTP in an ongoing P-IIb study
Ref: Takeda | Image: Takeda | Press Release
Related News:- Takeda’s Fruquintinib Gains the CHMP’s Positive Opinion for Previously Treated Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
